Wen PY, Kesari S: Malignant gliomas in adults. N Engl J Med. 2008, 359: 492-507. 10.1056/NEJMra0708126.
CAS
PubMed
Google Scholar
de Tayrac M, Etcheverry A, Aubry M, Saikali S, Hamlat A, Quillien V, Le Treut A, Galibert MD, Mosser J: Integrative genome-wide analysis reveals a robust genomic glioblastoma signature associated with copy number driving changes in gene expression. Genes Chromosomes Cancer. 2009, 48: 55-68. 10.1002/gcc.20618.
CAS
PubMed
Google Scholar
Nigro JM, Misra A, Zhang L, Smirnov I, Colman H, Griffin C, Ozburn N, Chen M, Pan E, Koul D, et al: Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res. 2005, 65: 1678-1686. 10.1158/0008-5472.CAN-04-2921.
CAS
PubMed
Google Scholar
Herman JG, Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003, 349: 2042-2054. 10.1056/NEJMra023075.
CAS
PubMed
Google Scholar
Karpf AR, Matsui S: Genetic disruption of cytosine DNA methyltransferase enzymes induces chromosomal instability in human cancer cells. Cancer Res. 2005, 65: 8635-8639. 10.1158/0008-5472.CAN-05-1961.
CAS
PubMed
Google Scholar
Garcia-Manero G: Demethylating agents in myeloid malignancies. Curr Opin Oncol. 2008, 20: 705-710. 10.1097/CCO.0b013e328313699c.
CAS
PubMed
Google Scholar
Mack GS: Epigenetic cancer therapy makes headway. J Natl Cancer Inst. 2006, 98: 1443-1444.
PubMed
Google Scholar
Watanabe T, Yokoo H, Yokoo M, Yonekawa Y, Kleihues P, Ohgaki H: Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas. J Neuropathol Exp Neurol. 2001, 60: 1181-1189.
CAS
PubMed
Google Scholar
Nakamura M, Yonekawa Y, Kleihues P, Ohgaki H: Promoter hypermethylation of the RB1 gene in glioblastomas. Lab Invest. 2001, 81: 77-82.
CAS
PubMed
Google Scholar
Costello JF, Berger MS, Huang HS, Cavenee WK: Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res. 1996, 56: 2405-2410.
CAS
PubMed
Google Scholar
Bello MJ, Rey JA: The p53/Mdm2/p14ARF cell cycle control pathway genes may be inactivated by genetic and epigenetic mechanisms in gliomas. Cancer Genet Cytogenet. 2006, 164: 172-173. 10.1016/j.cancergencyto.2005.07.002.
CAS
PubMed
Google Scholar
Amatya VJ, Naumann U, Weller M, Ohgaki H: TP53 promoter methylation in human gliomas. Acta Neuropathol. 2005, 110: 178-184. 10.1007/s00401-005-1041-5.
CAS
PubMed
Google Scholar
Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009, 10: 459-466. 10.1016/S1470-2045(09)70025-7.
CAS
PubMed
Google Scholar
Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, et al: Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 2008, 9: 29-38. 10.1016/S1470-2045(07)70384-4.
PubMed
Google Scholar
Keshet I, Schlesinger Y, Farkash S, Rand E, Hecht M, Segal E, Pikarski E, Young RA, Niveleau A, Cedar H, Simon I: Evidence for an instructive mechanism of de novo methylation in cancer cells. Nat Genet. 2006, 38: 149-153. 10.1038/ng1719.
CAS
PubMed
Google Scholar
Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM, Chevalier B, Johnstone SE, Cole MF, Isono K, et al: Control of developmental regulators by Polycomb in human embryonic stem cells. Cell. 2006, 125: 301-313. 10.1016/j.cell.2006.02.043.
CAS
PubMed
PubMed Central
Google Scholar
Kim TY, Zhong S, Fields CR, Kim JH, Robertson KD: Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. Cancer Res. 2006, 66: 7490-7501. 10.1158/0008-5472.CAN-05-4552.
CAS
PubMed
Google Scholar
Foltz G, Yoon JG, Lee H, Ryken TC, Sibenaller Z, Ehrich M, Hood L, Madan A: DNA methyltransferase-mediated transcriptional silencing in malignant glioma: a combined whole-genome microarray and promoter array analysis. Oncogene. 2009, 28: 2667-2677. 10.1038/onc.2009.122.
CAS
PubMed
Google Scholar
Wu X, Rauch TA, Zhong X, Bennett WP, Latif F, Krex D, Pfeifer GP: CpG island hypermethylation in human astrocytomas. Cancer Res. 2010, 70: 2718-2727. 10.1158/0008-5472.CAN-09-3631.
CAS
PubMed
PubMed Central
Google Scholar
Martinez R, Martin-Subero JI, Rohde V, Kirsch M, Alaminos M, Fernandez AF, Ropero S, Schackert G, Esteller M: A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics. 2009, 4: 255-264.
CAS
PubMed
Google Scholar
Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, et al: Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010, 17: 510-522. 10.1016/j.ccr.2010.03.017.
CAS
PubMed
PubMed Central
Google Scholar
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114: 97-109. 10.1007/s00401-007-0243-4.
PubMed
PubMed Central
Google Scholar
Kang MR, Kim MS, Oh JE, Kim YR, Song SY, Seo SI, Lee JY, Yoo NJ, Lee SH: Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer. 2009, 125: 353-355. 10.1002/ijc.24379.
CAS
PubMed
Google Scholar
Martinez R, Schackert G: Epigenetic aberrations in malignant gliomas: an open door leading to better understanding and treatment. Epigenetics. 2007, 2: 147-150. 10.4161/epi.2.3.5049.
PubMed
Google Scholar
Bulk E, Sargin B, Krug U, Hascher A, Jun Y, Knop M, Kerkhoff C, Gerke V, Liersch R, Mesters RM, et al: S100A2 induces metastasis in non-small cell lung cancer. Clin Cancer Res. 2009, 15: 22-29. 10.1158/1078-0432.CCR-08-0953.
CAS
PubMed
Google Scholar
Tseng MY, Liu SY, Chen HR, Wu YJ, Chiu CC, Chan PT, Chiang WF, Liu YC, Lu CY, Jou YS, Chen JY: Serine protease inhibitor (SERPIN) B1 promotes oral cancer cell motility and is over-expressed in invasive oral squamous cell carcinoma. Oral Oncol. 2009, 45: 771-776. 10.1016/j.oraloncology.2008.11.013.
CAS
PubMed
Google Scholar
Alaminos M, Davalos V, Ropero S, Setien F, Paz MF, Herranz M, Fraga MF, Mora J, Cheung NK, Gerald WL, Esteller M: EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. Cancer Res. 2005, 65: 2565-2571. 10.1158/0008-5472.CAN-04-4283.
CAS
PubMed
Google Scholar
Kannan-Thulasiraman P, Seachrist DD, Mahabeleshwar GH, Jain MK, Noy N: Fatty acid binding protein 5 and PPAR{beta}/{delta} are critical mediators of EGFR-induced carcinoma cell growth. J Biol Chem. 2010
Google Scholar
Miura T, Nishinaka T, Terada T: Different functions between human monomeric carbonyl reductase 3 and carbonyl reductase 1. Mol Cell Biochem. 2008, 315: 113-121. 10.1007/s11010-008-9794-5.
CAS
PubMed
Google Scholar
Takenaka K, Ogawa E, Oyanagi H, Wada H, Tanaka F: Carbonyl reductase expression and its clinical significance in non-small-cell lung cancer. Cancer Epidemiol Biomarkers Prev. 2005, 14: 1972-1975. 10.1158/1055-9965.EPI-05-0060.
CAS
PubMed
Google Scholar
Nagarajan RP, Costello JF: Epigenetic mechanisms in glioblastoma multiforme. Semin Cancer Biol. 2009, 19: 188-197. 10.1016/j.semcancer.2009.02.005.
CAS
PubMed
Google Scholar
Quinlan KG, Verger A, Yaswen P, Crossley M: Amplification of zinc finger gene 217 (ZNF217) and cancer: when good fingers go bad. Biochim Biophys Acta. 2007, 1775: 333-340.
CAS
PubMed
Google Scholar
Banck MS, Li S, Nishio H, Wang C, Beutler AS, Walsh MJ: The ZNF217 oncogene is a candidate organizer of repressive histone modifiers. Epigenetics. 2009, 4: 100-106. 10.4161/epi.4.2.7953.
CAS
PubMed
Google Scholar
Feng L, Hatten ME, Heintz N: Brain lipid-binding protein (BLBP): a novel signaling system in the developing mammalian CNS. Neuron. 1994, 12: 895-908. 10.1016/0896-6273(94)90341-7.
CAS
PubMed
Google Scholar
Kaloshi G, Mokhtari K, Carpentier C, Taillibert S, Lejeune J, Marie Y, Delattre JY, Godbout R, Sanson M: FABP7 expression in glioblastomas: relation to prognosis, invasion and EGFR status. J Neurooncol. 2007, 84: 245-248. 10.1007/s11060-007-9377-4.
PubMed
Google Scholar
Jung Y, Park J, Bang YJ, Kim TY: Gene silencing of TSPYL5 mediated by aberrant promoter methylation in gastric cancers. Lab Invest. 2008, 88: 153-160. 10.1038/labinvest.3700706.
CAS
PubMed
Google Scholar
Kim EJ, Lee SY, Kim TR, Choi SI, Cho EW, Kim KC, Kim IG: TSPYL5 is involved in cell growth and the resistance to radiation in A549 cells via the regulation of p21(WAF1/Cip1) and PTEN/AKT pathway. Biochem Biophys Res Commun. 2010, 392: 448-453. 10.1016/j.bbrc.2010.01.045.
CAS
PubMed
Google Scholar
Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, et al: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006, 9: 157-173. 10.1016/j.ccr.2006.02.019.
CAS
PubMed
Google Scholar
Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010, 17: 98-110. 10.1016/j.ccr.2009.12.020.
CAS
PubMed
PubMed Central
Google Scholar
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005, 352: 987-996. 10.1056/NEJMoa043330.
CAS
PubMed
Google Scholar
Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R, Crooks D, Husband D, Shenoy A, Brodbelt A, et al: Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer. 2009, 101: 124-131. 10.1038/sj.bjc.6605127.
CAS
PubMed
PubMed Central
Google Scholar
Stolt CC, Rehberg S, Ader M, Lommes P, Riethmacher D, Schachner M, Bartsch U, Wegner M: Terminal differentiation of myelin-forming oligodendrocytes depends on the transcription factor Sox10. Genes Dev. 2002, 16: 165-170. 10.1101/gad.215802.
CAS
PubMed
PubMed Central
Google Scholar
Salvati M, Formichella AI, D'Elia A, Brogna C, Frati A, Giangaspero F, Delfini R, Santoro A: Cerebral glioblastoma with oligodendrogliomal component: analysis of 36 cases. J Neurooncol. 2009, 94: 129-134. 10.1007/s11060-009-9815-6.
PubMed
Google Scholar